Visceral adiposity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Eyadéma died suddenly on 5 February 2005. According to the Togolese Constitution, after the president's death, the president of the National Assembly should become acting president. At the time of Eyadéma's death, the National Assembly president Fambaré Ouattara Natchaba was out of the country, and Gnassingbé was thus sworn in as president by the Togolese Army to "ensure stability". Many believe that Natchaba did not want to come back to Togo due to fears of assassination by the Gnassingbé clan. The army wanted him to resign his position and allow Gnassingbé to legally take over. The African Union denounced Gnassingbé's assumption of power as a military coup.
== Toxicity == The β-glycosidic bond between glucose and the hydroxyl group at C5 on the pyrimidine ring are hydrolysed to yield the aglycone of vicine, divicine (2,6-diamino-4,5-dihydroxypyrimidine). These aglycones have a strong oxidising capacity for glutathione. In healthy individuals, this is not a problem, as glutathione can be reduced quickly enough to regenerate it. In individuals with a deficiency for glucose 6-phosphate dehydrogenase (G6PD) however, this results in haemolytic anaemia.
Evidence employing retro-enantio N-methylated peptides, or those with alternating L and D amino acids, as inhibitors of beta-amyloid aggregation is consistent with alpha-sheet being the main material of the amyloid precursor.
Sources: en.wikipedia.org
==== Saddle Nose ==== When performing a septoplasty as part of a rhinoplasty, it is recommended to leave an L-strut of at least 1cm. The L-strut is a dorsal and caudal portion of the septum that is preserved. If the septum is unsupported, the bridge of the nose can sink, resulting in a "saddle nose" deformity, usually caused by over-resection of the septal L-strut. This may necessitate structural reconstruction with autologous cartilage or bone grafts.
The four substrates of this enzyme are taxifolin, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are dihydrogossypetin, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is phenol,NADPH:oxygen oxidoreductase (2-hydroxylating). Other names in common use include phenol hydroxylase, and phenol o-hydroxylase. It uses flavin adenine dinucleotide as a second cofactor. The systematic name of this enzyme class is taxifolin,NAD(P)H:oxygen oxidoreductase (8-hydroxylating). This enzyme is also called taxifolin hydroxylase.
Because bacteria are prokaryotes, they are not equipped with the full enzymatic machinery to accomplish the required post-translational modifications or molecular folding. Hence, multi-domain eukaryotic proteins expressed in bacteria often are non-functional. Also, many proteins become insoluble as inclusion bodies that are difficult to recover without harsh denaturants and subsequent cumbersome protein-refolding. To address these concerns, expressions systems using multiple eukaryotic cells were developed for applications requiring the proteins be conformed as in, or closer to eukaryotic organisms: cells of plants (i.e. tobacco), of insects or mammalians (i.e. bovines) are transfected with genes and cultured in suspension and even as tissues or whole organisms, to produce fully folded proteins. Mammalian in vivo expression systems have however low yield and other limitations (time-consuming, toxicity to host cells,..). To combine the high yield/productivity and scalable protein features of bacteria and yeast, and advanced epigenetic features of plants, insects and mammalians systems, other protein production systems are developed using unicellular eukaryotes (i.e. non-pathogenic 'Leishmania' cells).
Sources: en.wikipedia.org
Bush took office during an economic recession in the wake of the bursting of the dot-com bubble. The September 11 terrorist attacks also impacted the economy. His administration increased federal government spending from $1.8 trillion to $3 trillion (66%), while revenues increased from $2 trillion to $2.5 trillion (from 2000 to 2008). Individual income tax revenues increased by 14%, corporate tax revenues by 50%, and customs and duties by 40%. Discretionary defense spending was increased by 107%, discretionary domestic spending by 62%, Medicare spending by 131%, social security by 51%, and income security spending by 130%. Cyclically adjusted, revenues rose by 35% and spending by 65%. The increase in spending was more than under any predecessor since Lyndon B. Johnson. The number of economic regulation governmental workers increased by 91,196. The surplus in 2000 was $237 billion – the third consecutive surplus and the largest surplus ever. In 2001, Bush's budget estimated that there would be a $5.6 trillion surplus over the next ten years. Facing congressional opposition, Bush held town hall-style meetings across the U.S. to increase public support for his plan for a $1.35 trillion tax cut program, one of the largest tax cuts in history. Bush argued that unspent government funds should be returned to taxpayers, saying "the surplus is not the government's money. The surplus is the people's money." Federal Reserve chairman Alan Greenspan warned of a recession and Bush stated that a tax cut would stimulate the economy and create jobs. Treasury Secretary Paul H.
== Mitigation == Converting a drug into a prodrug can help avoid first-pass metabolism, thereby improving its bioavailability. In in vitro models, such as the use of microfluidic chips that simulate the gut and liver, allow first-pass metabolism to be studied more accurately, facilitating the development of drugs with better absorption profiles.
== Demographics == According to the 2021 Canadian census, 2023 representation order Racial groups: 83.2% White, 10.4% Black, 2.5% Arab, 2.2% Latin American, 1.4% Indigenous Languages: 87.3% French, 4.2% English, 2.3% Creole, 2.3% Spanish, 1.4% Arabic, 1.0% Italian Religions: 68.9% Christian (57.9% Catholic, 11.0% Other), 4.2% Muslim, 26.1% None Median income: $45,600 (2020) Average income: $53,750 (2020)
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.